Eckert & Ziegler to Acquire Radiation Product Business of HEK GmbH
Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement.
Eckert & Ziegler to Acquire Radiation Product Business of HEK GmbH Berlin, 16.03.2004. Eckert & Ziegler AG (ISIN DE 0005659700), a specialist for brachytherapy products used in the treatment of cancer, has acquired the radiation product business of HEK GmbH, Lübeck. The transaction includes production facilities in Lübeck and Braunschweig with about 30 employees, and HEK's European business for patient fixation devices. Main revenue generator of HEK's radiation product business have been high dose rate afterloaders for the treatment of cancer, and blood irradiation devices. As consideration for the business Eckert & Ziegler paid a mixture of cash and stocks valued in the lower single digit million range. In addition, the seller is entitled to an Earn-Out. Including the acquisition, and under the assumption that the EUR/Dollar ex- change rate remains stable, Eckert & Ziegler AG for 2004 anticipates revenues to grow about 20% to 36 mm EUR and a result of approximately 0.40 EUR per share.
The Executive Board
For further questions please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Phone: +49 (0) 30 / 94 10 84-138
http://www.ezag.de
end of ad-hoc-announcement
(c)DGAP 16.03.2004
WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart 161040 Mär 04
Eckert & Ziegler to Acquire Radiation Product Business of HEK GmbH Berlin, 16.03.2004. Eckert & Ziegler AG (ISIN DE 0005659700), a specialist for brachytherapy products used in the treatment of cancer, has acquired the radiation product business of HEK GmbH, Lübeck. The transaction includes production facilities in Lübeck and Braunschweig with about 30 employees, and HEK's European business for patient fixation devices. Main revenue generator of HEK's radiation product business have been high dose rate afterloaders for the treatment of cancer, and blood irradiation devices. As consideration for the business Eckert & Ziegler paid a mixture of cash and stocks valued in the lower single digit million range. In addition, the seller is entitled to an Earn-Out. Including the acquisition, and under the assumption that the EUR/Dollar ex- change rate remains stable, Eckert & Ziegler AG for 2004 anticipates revenues to grow about 20% to 36 mm EUR and a result of approximately 0.40 EUR per share.
The Executive Board
For further questions please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Phone: +49 (0) 30 / 94 10 84-138
http://www.ezag.de
end of ad-hoc-announcement
(c)DGAP 16.03.2004
WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart 161040 Mär 04